SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ketamine (5%) Formulation

Version 1.4  Revision Date: 09.04.2021  SDS Number: 3983605-00005  Date of last issue: 10.10.2020
Date of first issue: 14.02.2019

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name: Ketamine (5%) Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture: Veterinary product

1.3 Details of the supplier of the safety data sheet
Company: MSD
Kilsheelan
Clonmel Tipperary, IE

Telephone: 353-51-601000

E-mail address of person responsible for the SDS: EHSDATA STEWARD@msd.com

1.4 Emergency telephone number
+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008)
Reproductive toxicity, Category 2

H361d: Suspected of damaging the unborn child.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms:

Signal word: Warning

Hazard statements:
H361d Suspected of damaging the unborn child.

Precautionary statements:

Prevention:
P201 Obtain special instructions before use.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
Ketamine (5%) Formulation

Storage:
P405 Store locked up.

Hazardous components which must be listed on the label:
Ketamine hydrochloride

Additional Labelling
The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 5%

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketamine hydrochloride</td>
<td>1867-66-9</td>
<td>217-484-6</td>
<td></td>
<td></td>
<td>Acute Tox. 4; H302 Skin Irrit. 2; H315 Eye Irrit. 2; H319 Repr. 2; H361d STOT RE 2; H373 (Kidney, Liver, Brain)</td>
<td>&gt;= 3 - &lt; 10</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection,
and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled

If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact

In case of contact, immediately flush skin with plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact

Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed

If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks
Suspected of damaging the unborn child.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment
Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media
Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media
None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting
Exposure to combustion products may be a hazard to health.

Hazardous combustion products
Carbon oxides
Chlorine compounds
Nitrogen oxides (NOx)

5.3 Advice for firefighters

Special protective equipment for firefighters
In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing method
Use extinguishing measures that are appropriate to local cir-
SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions:
- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g. by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
- Soak up with inert absorbent material.
- For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
- Clean up remaining materials from spill with suitable absorbent.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures:
- See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation:
- Use only with adequate ventilation.
- Do not get on skin or clothing.
- Do not breathe mist or vapours.
- Do not swallow.
- Avoid contact with eyes.
- Handle in accordance with good industrial hygiene and safety
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ketamine (5%) Formulation

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities
Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.
Advice on common storage: Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)
Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketamine hydrochloride</td>
<td>1867-66-9</td>
<td>TWA</td>
<td>10 µg/m3 (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>100 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures
Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment
Eye protection: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material: Chemical-resistant gloves
Remarks: Consider double gloving.

Skin and body protection
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Equipment should conform to NS EN 143

Filter type: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

<table>
<thead>
<tr>
<th>Physical state</th>
<th>liquid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>No data available</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>No data available</td>
</tr>
</tbody>
</table>
Ketamine (5%) Formulation

Solubility(ies)
Water solubility : soluble
Partition coefficient: n-octanol/water : Not applicable
Vapour pressure : No data available
Relative density : No data available
Density : No data available
Relative vapour density : No data available
Particle characteristics
Particle size : Not applicable

9.2 Other information
Explosives : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Evaporation rate : No data available
Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : None known.

10.5 Incompatible materials
Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ketamine (5%) Formulation

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

Components:

Ketamine hydrochloride:
Acute oral toxicity: LD50 (Rat): 447 mg/kg
LD50 (Mouse): 617 mg/kg

Acute toxicity (other routes of administration): LD50 (Rat): 59 mg/kg
Application Route: Intravenous
LD50 (Mouse): 59 mg/kg
Application Route: Intramuscular
LD50 (Mouse): 356 mg/kg
Application Route: Intramuscular
LD50 (Guinea pig): 361 mg/kg
Application Route: Intramuscular
LD50 (Rat): 224 mg/kg
Application Route: Intraperitoneal

Skin corrosion/irritation
Not classified based on available information.

Components:

Ketamine hydrochloride:
Species: Rabbit
Result: irritating

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Ketamine hydrochloride:
Species: Rabbit
Result: irritating
Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.

Carcinogenicity
Not classified based on available information.

Reproductive toxicity
Suspected of damaging the unborn child.

Components:

**Ketamine hydrochloride:**
Effects on foetal development
- **Test Type:** Development
- **Species:** Rat
- **Application Route:** Intramuscular
- **Developmental Toxicity:** NOAEL: 120 mg/kg body weight
- **Target Organs:** Kidney, Liver, Heart
- **Result:** No teratogenic effects

**Test Type:** Development
- **Species:** Rabbit
- **Application Route:** Intramuscular
- **Developmental Toxicity:** LOAEL: 20 mg/kg body weight
- **Symptoms:** Skeletal and visceral variations
- **Result:** Effects on prenatal and postnatal growth.

**Test Type:** Development
- **Species:** Rat
- **Application Route:** Intramuscular
- **Symptoms:** Skeletal and visceral variations
- **Result:** Effects on prenatal and postnatal growth.

**Test Type:** Development
- **Species:** Rabbit
- **Application Route:** Intramuscular
- **Developmental Toxicity:** LOAEL: 60 mg/kg body weight
- **Symptoms:** Skeletal and visceral variations
- **Result:** Effects on prenatal and postnatal growth.

**Test Type:** Development
- **Species:** Monkey
- **Application Route:** Intramuscular
- **Target Organs:** Brain
- **Result:** Effects on prenatal and postnatal growth.

Reproductive toxicity - Assessment
- Suspected of damaging the unborn child.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ketamine (5%) Formulation

Version 1.4
Revision Date: 09.04.2021
SDS Number: 3983605-00005
Date of last issue: 10.10.2020
Date of first issue: 14.02.2019

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Components:

Ketamine hydrochloride:
Exposure routes: Skin contact
Target Organs: Kidney, Liver, Brain
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Ketamine hydrochloride:
Species: Mouse
LOAEL: 30 mg/kg
Application Route: Intraperitoneal
Exposure time: 3 Months
Target Organs: Kidney, Liver, Bladder
Remarks: Significant toxicity observed in testing

Species: Mouse
LOAEL: 30 mg/kg
Application Route: Intraperitoneal
Exposure time: 6 Months
Target Organs: Kidney, Liver, Bladder
Remarks: Significant toxicity observed in testing

Species: Mouse
LOAEL: 30 mg/kg
Application Route: Intraperitoneal
Exposure time: 28 Weeks
Target Organs: Kidney
Remarks: Significant toxicity observed in testing

Species: Mouse
LOAEL: 30 mg/kg
Application Route: Intraperitoneal
Exposure time: 30 Days
Target Organs: Brain, Liver
Remarks: Significant toxicity observed in testing

Species: Monkey
LOAEL: 1 mg/kg
Application Route: Intraperitoneal
Exposure time: 6 Months
Target Organs: Brain
Remarks: Significant toxicity observed in testing
Aspiration toxicity
Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:
Ketamine hydrochloride:
Ingestion: Symptoms: The most common side effects are: central nervous system effects, hypertension, Dizziness, Headache, Nausea, Drowsiness

SECTION 12: Ecological information

12.1 Toxicity

Components:
Ketamine hydrochloride:
Ecotoxicology Assessment
Acute aquatic toxicity: Toxic effects cannot be excluded
Chronic aquatic toxicity: Toxic effects cannot be excluded

12.2 Persistence and degradability
No data available

12.3 Bioaccumulative potential

Components:
Ketamine hydrochloride:
Partition coefficient: n-octanol/water: log Pow: 2.18

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment

Product:
Assessment: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or
very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

Product: Endocrine disrupting potential
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Maritime transport in bulk according to IMO instruments
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture
REACH - Restrictions on the manufacture, placing on : Conditions of restriction for the fol-
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ketamine (5%) Formulation

Version 1.4 Revision Date: 09.04.2021 SDS Number: 3983605-00005 Date of last issue: 10.10.2020
Date of first issue: 14.02.2019

According to Annex XVII articles (EC) No. 1907/2006 the following entries should be considered:
- **Number on list 3**

**REACH** - Candidate List of Substances of Very High Concern for Authorisation (Article 59):
- Not applicable

**REACH** - List of substances subject to authorisation (Annex XIV):
- Not applicable

**Regulation (EC) No 1005/2009 on substances that deplete the ozone layer**:
- Not applicable

**Regulation (EU) 2019/1021 on persistent organic pollutants (recast)**:
- Not applicable

**Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals**:
- Not applicable

- Not applicable

**Other regulations**:
- Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

**The components of this product are reported in the following inventories**:
- **AICS**: not determined
- **DSL**: not determined
- **IECSC**: not determined

**15.2 Chemical safety assessment**
- A Chemical Safety Assessment has not been carried out.

**SECTION 16: Other information**

- Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

**Full text of H-Statements**
- **H302**: Harmful if swallowed.
- **H315**: Causes skin irritation.
- **H319**: Causes serious eye irritation.
- **H361d**: Suspected of damaging the unborn child.
- **H373**: May cause damage to organs through prolonged or repeated exposure in contact with skin.

**Full text of other abbreviations**
- **Acute Tox.**: Acute toxicity
- **Eye Irrit.**: Eye irritation
- **Repr.**: Reproductive toxicity
- **Skin Irrit.**: Skin irritation
- **STOT RE**: Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Rail
Ketamine (5%) Formulation

Version: 1.4
Revision Date: 09.04.2021
SDS Number: 3983605-00005
Date of last issue: 10.10.2020
Date of first issue: 14.02.2019

Further information

Classification of the mixture:
Repr. 2 H361d

Classification procedure:
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NO / EN